Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Community Ment Health J ; 60(1): 115-123, 2024 01.
Article in English | MEDLINE | ID: mdl-38105337

ABSTRACT

This study sought to evaluate the impact of telepsychiatry during the COVID-19 pandemic among patients discharged from psychiatric inpatient units in the New York City Health and Hospitals Corporation system. We compared patients discharged to telepsychiatry (April 2020, n = 739) and in-person follow-up (May 2019, n = 527); we collected number, timing and attendance for follow-up appointments and number and timing of emergency room (ER) visits and readmissions. We used logistic regression to evaluate the odds of having these encounters and Kaplan-Meier analyses to compare time to these encounters. Patients discharged in 2020 were more likely to have a follow-up (29.4 vs. 19.9%, p < 0.001) and an ER visit or readmission (40.5 vs. 28.7%, p < 0.001). Kaplan-Meier analyses showed shorter time to first follow-up (chi-square = 14.69, d.f.=1, p < 0.0001, follow-ups = 322) and ER visit or readmission (chi-square = 19.57, d.f.=1, p < 0.0001, ER visits or admissions = 450) in the 2020 cohort. In multivariable analyses, patients discharged in 2020 were more likely to have a follow-up visit (adjusted OR 1.85, 95% confidence interval 1.40, 2.45, p < 0.0001). We found an increase in psychiatric service utilization during the pandemic, with an increase in and shorter time until outpatient visits and ER visits or readmissions. Although increased use of psychiatric services during the height of the COVID-19 pandemic is encouraging, it also points to the depth of the crisis among vulnerable populations; this pattern warrants further exploration and intervention.


Subject(s)
COVID-19 , Psychiatry , Telemedicine , Humans , COVID-19/epidemiology , Pandemics , New York City/epidemiology , Retrospective Studies
3.
Acad Psychiatry ; 45(2): 174-179, 2021 Apr.
Article in English | MEDLINE | ID: mdl-33409938

ABSTRACT

OBJECTIVE: One possible factor associated with choosing psychiatry as a career is students rating their psychiatry clerkship as excellent. Although this suggests that an excellent clerkship may improve recruitment into psychiatry, to our knowledge there has never been a multi-site survey study of graduating medical students that identify what factors lead to an excellent clerkship rating. The purpose of this study was to determine factors that medical student find important for an excellent psychiatry clerkship experience. METHODS: A total of 1457 graduating medical students at eight institutions were sent a 22-item Likert-type survey about what clinical and administrative factors they considered when rating their psychiatry clerkship via email in the fall of their last year. 357 (24.5%) responded and Z-test, t-tests, and multiple regression analyses were carried out. RESULTS: The factors which students rated higher than the mean included planned application to psychiatry residency, clear expectations, a transparent grading process, feeling part of a team, timely feedback by faculty, and a competent clerkship coordinator and director. Lectures, active learning, and self-study were rated as less pertinent, and the overall clerkship rating did differ between students going into psychiatry versus other specialties. CONCLUSIONS: Although the low response undermines the validity of findings, by improving the administration of the clerkship with clear expectations, grading, feedback, and by encouraging clinical teams to fully integrate students clerkship ratings might improve which could potentially improve recruitment. Future research could further quantify and qualify these parameters and compare psychiatric clerkships to other clerkships.


Subject(s)
Clinical Clerkship , Psychiatry , Students, Medical , Humans , Problem-Based Learning , Psychiatry/education , Surveys and Questionnaires
4.
J Biol Chem ; 282(26): 18722-31, 2007 Jun 29.
Article in English | MEDLINE | ID: mdl-17475625

ABSTRACT

Because the mechanisms of Helicobacter pylori-induced gastric injury are incompletely understood, we examined the hypothesis that H. pylori induces matrix metalloproteinase-1 (MMP-1) secretion, with potential to disrupt gastric stroma. We further tested the role of CagA, an H. pylori virulence factor, in MMP-1 secretion. Co-incubation of AGS cells with Tx30a, an H. pylori strain lacking the cagA virulence gene, stimulated MMP-1 secretion, confirming cagA-independent secretion. Co-incubation with strain 147C (cagA(+)) resulted in CagA translocation into AGS cells and increased MMP-1 secretion relative to Tx30a. Transfection of cells with the recombinant 147C cagA gene also induced MMP-1 secretion, indicating that CagA can independently stimulate MMP-1 secretion. Co-incubation with strain 147A, containing a cagA gene that lacks an EPIYA tyrosine phosphorylation motif, as well as transfection with 147A cagA, yielded an MMP-1 secretion intermediate between no treatment and 147C, indicating that CagA tyrosine phosphorylation regulates cellular signaling in this model system. H. pylori induced activation of the MAP kinase ERK, with CagA-independent (early) and dependent (later) components. MEK inhibitors UO126 and PD98059 inhibited both CagA-independent and -dependent MMP-1 secretion, whereas p38 inhibition enhanced MMP-1 secretion and ERK activation, suggesting p38 negative regulation of MMP-1 and ERK. These data indicate H. pylori effects on host epithelial MMP-1 expression via ERK, with p38 playing a potential regulatory role.


Subject(s)
Antigens, Bacterial/metabolism , Bacterial Proteins/metabolism , Extracellular Signal-Regulated MAP Kinases/metabolism , Helicobacter Infections/microbiology , Helicobacter pylori/metabolism , Matrix Metalloproteinase 1/metabolism , Antigens, Bacterial/genetics , Bacterial Proteins/genetics , Cell Line, Tumor , Epithelial Cells/enzymology , Epithelial Cells/microbiology , Genotype , Helicobacter Infections/metabolism , Helicobacter pylori/genetics , Helicobacter pylori/pathogenicity , Humans , MAP Kinase Signaling System/physiology , Neoplasms, Glandular and Epithelial , Stomach Neoplasms , Transfection , Virulence
5.
J Biol Chem ; 280(11): 9973-9, 2005 Mar 18.
Article in English | MEDLINE | ID: mdl-15640153

ABSTRACT

Because matrix metalloproteinases (MMPs) play roles in inflammatory tissue injury, we asked whether MMP secretion by gastric epithelial cells may contribute to gastric injury in response to signals involved in Helicobacter pylori-induced inflammation and/or cyclooxygenase inhibition. Tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and epidermal growth factor (EGF) stimulated gastric cell MMP-1 secretion, indicating that MMP-1 secretion occurs in inflammatory as well as non-inflammatory situations. MMP-1 secretion required activation of the MAPK Erk and subsequent protein synthesis but was down-regulated by the alternate MAPK, p38. In contrast, secretion of MMP-13 was stimulated by TNF-alpha/IL-1beta but not EGF and was Erk-independent and mediated by p38. MMP-13 secretion was more rapid (peak, 6 h) than MMP-1 (peak > or =30 h) and only partly depended on protein synthesis, suggesting initial release of a pre-existing MMP-13 pool. Therefore, MMP-1 and MMP-13 secretion are differentially regulated by MAPKs. MMP-1 secretion was regulated by E prostaglandins (PGEs) in an Erk-dependent manner. PGEs enhanced Erk activation and MMP-1 secretion in response to EGF but inhibited Erk and MMP-1 when TNF-alpha and IL-1beta were the stimuli, indicating that the effects of PGEs on gastric cell responses are context-dependent. These data show that secretion of MMPs is differentially regulated by MAPKs and suggest mechanisms through which H. pylori infection and/or cyclooxygenase inhibition may induce epithelial cell signaling to contribute to gastric ulcerogenesis.


Subject(s)
Epithelial Cells/metabolism , Gastric Mucosa/metabolism , MAP Kinase Signaling System , Matrix Metalloproteinases/metabolism , Prostaglandins E/metabolism , Cell Line, Tumor , Collagenases/metabolism , Cycloheximide/pharmacology , Cyclooxygenase Inhibitors/pharmacology , Down-Regulation , Enzyme Activation , Enzyme Inhibitors/pharmacology , Epidermal Growth Factor/metabolism , Epithelial Cells/microbiology , Extracellular Signal-Regulated MAP Kinases/metabolism , Gene Expression Regulation, Enzymologic , Helicobacter pylori/metabolism , Humans , Inflammation , Interleukin-1/metabolism , Kinetics , Matrix Metalloproteinase 1/metabolism , Matrix Metalloproteinase 13 , Models, Biological , Protein Synthesis Inhibitors/pharmacology , Signal Transduction , Stomach/microbiology , Time Factors , Tumor Necrosis Factor-alpha/metabolism , p38 Mitogen-Activated Protein Kinases/metabolism
6.
Br J Pharmacol ; 142(6): 973-82, 2004 Jul.
Article in English | MEDLINE | ID: mdl-15210577

ABSTRACT

1 Nabumetone is a prodrug that is converted in vivo into 6-methoxy-2-naphthylacetic acid (6MNA), a cyclooxygenase inhibitor with anti-inflammatory properties. We tested the effects of nabumetone and 6MNA on the inflammatory responses of synovial fibroblasts (SFs). 2 Brief exposures to 6MNA (50-150 microm) had no effect on IL-1beta/TNF-alpha (each 20 ng ml(-1))-stimulated Erk activation. Longer exposures depleted prostaglandin E1 (PGE1) as much as 70%, and stimulated Erk as much as 300%. Nabumetone (150 microm) inhibited Erk activation by 60-80%. 6MNA (50-150 microm) stimulated (approximately 200%) and nabumetone (150 microm) inhibited (approximately 50%) matrix metalloproteinase (MMP)-1, but not MMP-13 secretion from SFs. 3 6MNA stimulation of MMP-1 secretion was inhibited approximately 30% by PGE1 (1 microm) and approximately 80% by the Erk pathway inhibitor UO126 (10 microm), confirming that PGE depletion and Erk activation mediate MMP-1 secretion by 6MNA. 4 Consistent with its role as an Erk inhibitor, nabumetone (150 microm) abrogated 6MNA enhancement of MMP-1 secretion. 5 UO126 (10 microm) and nabumetone (150 microm) inhibited (approximately 70 and 40%, respectively), but 6MNA (150 microm) enhanced (approximately 40%), NF-kappaB activation. 6 Our data indicate that 6MNA shares with other COX inhibitors several proinflammatory effects on synovial fibroblasts. In contrast, nabumetone demonstrates anti-inflammatory and potentially arthroprotective effects that have not been previously appreciated.


Subject(s)
Extracellular Signal-Regulated MAP Kinases/metabolism , Fibroblasts/metabolism , Metalloendopeptidases/metabolism , NF-kappa B/metabolism , Prostaglandins E/metabolism , Alprostadil/metabolism , Analysis of Variance , Animals , Butadienes/pharmacology , Butanones/pharmacology , Cell Line , Cell Survival/drug effects , Cyclooxygenase Inhibitors/pharmacology , Dinoprost/metabolism , Dose-Response Relationship, Drug , Enzyme Inhibitors/pharmacology , Extracellular Signal-Regulated MAP Kinases/antagonists & inhibitors , Fibroblasts/cytology , Fibroblasts/drug effects , Imidazoles/pharmacology , Interleukin-1/pharmacology , Matrix Metalloproteinase 1/metabolism , Nabumetone , Naphthaleneacetic Acids/pharmacology , Nitric Oxide/biosynthesis , Nitriles/pharmacology , Phosphorylation/drug effects , Pyridines/pharmacology , Rabbits , Synovial Membrane/cytology , Synovial Membrane/drug effects , Synovial Membrane/metabolism , Tumor Necrosis Factor-alpha/pharmacology
7.
J Biol Chem ; 279(8): 7346-52, 2004 Feb 20.
Article in English | MEDLINE | ID: mdl-14660603

ABSTRACT

Post-translational modification of Ras proteins includes prenylcysteine-directed carboxyl methylation. Because Ras participates in Erk activation by epidermal growth factor (EGF), we tested whether Ras methylation regulates Erk activation. EGF stimulation of Erk was inhibited by AFC (N-acetyl-S-farnesyl-L-cysteine), an inhibitor of methylation, but not AGC (N-acetyl-S-geranyl-L-cysteine), an inactive analog of AFC. AFC inhibited Ras methylation as well as the activation of pathway enzymes between Ras and Erk but did not inhibit EGF receptor phosphorylation, confirming action at the level of Ras. Transient transfection of human prenylcysteine-directed carboxyl methyltransferase increased EGF-stimulated Erk activation. AFC but not AGC inhibited movement of transiently transfected green fluorescent protein-Ras from the cytosol to the plasma membrane of COS-1 cells and depleted green fluorescent protein-Ras from the plasma membrane in stably transfected Madin-Darby canine kidney cells, suggesting that methylation regulates Erk by ensuring proper membrane localization of Ras. However, when COS-1 cells were transfected with Ras complexed to CD8, plasma membrane localization of Ras was unaffected by AFC, yet EGF-stimulated Erk activation was inhibited by AFC. Thus, Ras methylation appears to regulate Erk activation both through the localization of Ras as well as the propagation of Ras-dependent signals.


Subject(s)
Acetylcysteine/analogs & derivatives , ras Proteins/chemistry , Acetylcysteine/pharmacology , Animals , CD8 Antigens/biosynthesis , COS Cells , Cell Line , Cell Membrane/metabolism , Dogs , Dose-Response Relationship, Drug , Enzyme Activation , Enzyme Inhibitors/pharmacology , Green Fluorescent Proteins , Luminescent Proteins/metabolism , Methylation , Mitogen-Activated Protein Kinases/metabolism , Phosphorylation , Plasmids/metabolism , Protein Binding , Protein Structure, Tertiary , Proto-Oncogene Proteins c-raf/metabolism , Time Factors , Transfection , ras Proteins/metabolism
8.
J Immunol ; 171(11): 6080-9, 2003 Dec 01.
Article in English | MEDLINE | ID: mdl-14634122

ABSTRACT

We examined the regulation of matrix metalloproteinase (MMP) production by mitogen-activated protein kinases and cyclooxygenases (COXs) in fibroblast-like synoviocytes (FLSCs). IL-1beta and TNF-alpha stimulated FLSC extracellular signal-regulated kinase (ERK) activation as well as MMP-1 and -13 release. Pharmacologic inhibitors of ERK inhibited MMP-1, but not MMP-13 expression. Whereas millimolar salicylates inhibited both ERK and MMP-1, nonsalicylate COX and selective COX-2 inhibitors enhanced stimulated MMP-1 release. Addition of exogenous PGE(1) or PGE(2) inhibited MMP-1, reversed the effects of COX inhibitors, and inhibited ERK activation, suggesting that COX-2 activity tonically inhibits MMP-1 production via ERK inhibition by E PGs. Exposure of FLSCs to nonselective COX and selective COX-2 inhibitors in the absence of stimulation resulted in up-regulation of MMP-1 expression in an ERK-dependent manner. Moreover, COX inhibition sufficient to reduce PGE levels increased ERK activity. Our data indicate that: 1) ERK activation mediates MMP-1 but not MMP-13 release from FLSCs, 2) COX-2-derived E PGs inhibit MMP-1 release from FLSCs via inhibition of ERK, and 3) COX inhibitors, by attenuating PGE inhibition of ERK, enhance the release of MMP-1 by FLSC.


Subject(s)
Down-Regulation/physiology , Fibroblasts/enzymology , Isoenzymes/physiology , Matrix Metalloproteinase 1/biosynthesis , Matrix Metalloproteinase Inhibitors , Mitogen-Activated Protein Kinases/antagonists & inhibitors , Prostaglandin-Endoperoxide Synthases/physiology , Prostaglandins E/physiology , Synovial Membrane/enzymology , Animals , Anti-Inflammatory Agents, Non-Steroidal , Aspirin/pharmacology , Cells, Cultured , Cyclooxygenase 2 , Enzyme Activation/drug effects , Enzyme Activation/immunology , Enzyme Inhibitors/pharmacology , Extracellular Space/drug effects , Extracellular Space/enzymology , Fibroblasts/drug effects , Fibroblasts/immunology , Fibroblasts/metabolism , Humans , Interleukin-1/pharmacology , Isoenzymes/antagonists & inhibitors , Matrix Metalloproteinase 1/metabolism , Membrane Proteins , Mitogen-Activated Protein Kinases/metabolism , Mitogen-Activated Protein Kinases/physiology , Rabbits , Signal Transduction/drug effects , Signal Transduction/physiology , Synovial Membrane/drug effects , Synovial Membrane/immunology , Synovial Membrane/metabolism , Tumor Necrosis Factor-alpha/pharmacology , Up-Regulation/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...